The short version
6 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Budesonide Inhalation Suspension
Budesonide · BUDESONIDE .5 mg/2mL · Inhalant · Oral · Preferred Pharmaceuticals Inc.
NDC 68788-7314-03 · 6 POUCH in 1 CARTON / 5 AMPULE in 1 POUCH / 2 mL in 1 AMPULE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.2%chance of a new FDA shortage posting for budesonide (other) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Preferred Pharmaceuticals Inc.United Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA205710
- TE code
- AN
- Approval date
- Nov 16, 2017
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Budesonide (Inhalant)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | BUDESONIDE .25 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | BUDESONIDE .25 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | BUDESONIDE .5 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | BUDESONIDE 1 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | BUDESONIDE 1 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | BUDESONIDE .5 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | BUDESONIDE .25 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Nephron Pharmaceuticals Corporation | BUDESONIDE .5 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Nephron Pharmaceuticals Corporation | BUDESONIDE .25 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals Inc. | BUDESONIDE .5 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Rising Pharma Holdings, Inc. | BUDESONIDE .5 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Rising Pharma Holdings, Inc. | BUDESONIDE .25 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Budesonide Inhalation Suspension — NDC 68788-7314-03," retrieved September 3, 2026, https://drugdashboards.com/drug/68788731403.
Free to cite with attribution — see how the data is put together.